Medication info
Lobahai Tablet 10/80 mg

Lobahai Tablet 10/80 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets/box[((10 tablets/PTP)*3)]
Approval status
Active

MFDS item code 202009006 · Approved 2020.12.18 · Insurance code 671706730

Summary

Main use
Treats hypertension and heart failure, improves dyslipidemia and atherosclerosis, and reduces the risk of cardiovascular disease and death
Who takes it
Adults · Children
Adult dose
This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose of valsartan is 80 mg orally once daily, regardless of sex or race. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for a creatinine clearance of 10 mL/min or greater. However, this medicine should not be administered to patients with a creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
◆ Valsartan 1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 2. Heart failure 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treats hypertension and heart failure, improves dyslipidemia and atherosclerosis, and reduces the risk of cardiovascular disease and death

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high sensitivity C-reactive protein
  • hypertension
View approved original text

This medication is used for patients who require the concurrent administration of Valsartan and Rosuvastatin. Valsartan is used for the treatment of essential hypertension and in patients with heart failure, particularly in cases of intolerance to ACE inhibitors, helping to reduce the risk of death in patients with left ventricular dysfunction following myocardial infarction. Meanwhile, Rosuvastatin is used as an adjunct to diet in patients with hypercholesterolemia and dyslipidemia, and is particularly important in the treatment of familial homozygous hypercholesterolemia. Additionally, it lowers total cholesterol and LDL cholesterol levels, delaying the progression of atherosclerosis and reducing the risks of cardiovascular diseases and stroke. Therefore, this combination medication is very effective for treating patients who have both hypertension and heart failure with hyperlipidemia.

How to take

Adult dose

This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose of valsartan is 80 mg orally once daily, regardless of sex or race. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into consideration. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for a creatinine clearance of 10 mL/min or greater. However, this medicine should not be administered to patients with a creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If a dose of 80 mg or more daily is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

◆ Valsartan 1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 2. Heart failure 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause severe harm to the fetus and newborn if used during pregnancy, and should be discontinued immediately upon confirmation of pregnancy. It should not be used in individuals with allergies to this drug, pregnant or breastfeeding women, patients with severe liver or kidney damage, or those with specific genetic disorders. Particular caution is required for the elderly, patients with reduced liver function, patients with hyperkalemia, and those with heart or kidney problems when using this medication, and their condition should be regularly monitored through blood tests if necessary. This drug can cause muscle pain or weakness, and in rare cases severe muscle damage, so any unusual muscle symptoms should prompt immediate consultation with a doctor. During treatment, liver function tests and muscle-related tests should be performed as needed, and if severe liver damage or muscle abnormalities are detected, the medication should be discontinued. This medication can interact with other drugs, so be sure to inform healthcare providers of any other medications being taken. Particularly, when used together with potassium-sparing diuretics or potassium supplements, potassium levels in the blood may reach dangerous levels, requiring caution. Women who are pregnant or planning to become pregnant should use appropriate contraception before starting this medication, and should discontinue immediately upon confirmation of pregnancy. Breastfeeding women are advised not to take this medication and should discontinue breastfeeding if it must be taken. This drug is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established. In cases of overdose, symptoms may include hypotension or decreased consciousness, requiring immediate medical attention; blood dialysis may not be effective. This medication should be kept out of reach of children, and transferring it to another container may alter its quality.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, asthenia, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferases, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory tract infection, edema, weakness, heightened tension, decreased motor function, confusion, rash, myalgia, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, pharyngitis, arthralgia, hypotension, orthostatic dizziness, orthostatic hypotension, renal dysfunction, hyperkalemia, drowsiness, vomiting, thirst, loss of appetite, malaise, vascular edema, erythema, itching, serum sickness, vasculitis, syncope, epistaxis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, decreased hemoglobin, peripheral neuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, forgetfulness, amnesia, memory disturbance, confusion, severe muscle weakness, ophthalmoplegia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly closed container that protects it from light. Additionally, it is important to store it at room temperature between 1 to 30 degrees Celsius to maintain its efficacy.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets/box[((10 tablets/PTP)*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.